<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurol</journal-id>
<journal-title-group>
<journal-title>Journal of Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0340-5354</issn>
<issn pub-type="epub">1432-1459</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28120042</article-id>
<article-id pub-id-type="pmc">5533817</article-id>
<article-id pub-id-type="publisher-id">8394</article-id>
<article-id pub-id-type="doi">10.1007/s00415-017-8394-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurological Update</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent advances in epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0492-9442</contrib-id>
<name>
<surname>Manford</surname>
<given-names>Mark</given-names>
</name>
<address>
<phone>(44) 1223 216759</phone>
<email>mark.manford@icloud.com</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>Department of Clinical Neurosciences, </institution><institution>Addenbrooke’s Hospital and University of Cambridge, </institution></institution-wrap>Hills Rd, Cambridge, CB2 0QQ UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>24</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>24</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>264</volume>
<issue>8</issue>
<fpage>1811</fpage>
<lpage>1824</lpage>
<history>
<date date-type="received">
<day>3</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>9</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">This paper reviews advances in epilepsy in recent years with an emphasis on therapeutics and underlying mechanisms, including status epilepticus, drug and surgical treatments. Lessons from rarer epilepsies regarding the relationship between epilepsy type, mechanisms and choice of antiepileptic drugs (AED) are explored and data regarding AED use in pregnancy are reviewed. Concepts evolving towards a move from treating seizures to treating epilepsy are discussed, both in terms of the mechanisms of epileptogenesis, and in terms of epilepsy’s broader comorbidity, especially depression.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Epilepsy</kwd>
<kwd>Classification</kwd>
<kwd>Status epilepticus</kwd>
<kwd>Treatment</kwd>
<kwd>Pregnancy</kwd>
<kwd>Epileptogenesis</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag GmbH Germany 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Definitions and classification</title>
<p id="Par2">Definitions in epilepsy have always been problematic [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. The disorder is characterised by seizures but not all seizures are due to epilepsy—febrile seizures or drug induced seizures, for example. Earlier classifications sought to reconcile these difficulties by describing different electroclinical syndromes but new data from modern imaging and genetics need to be incorporated.</p>
<p id="Par3">Diagnosis is difficult because in practice, the diagnostic electrical hallmark of epilepsy may be absent interictally, especially in adults or if seizures are infrequent and interictal epileptiform discharges may occasionally be present in those without seizures. Moreover, in some instances, an “epileptic EEG” may be associated with an epileptic encephalopathy, in which overt seizures may be few or none, such as Landau–Kleffner syndrome, and a cognitive disorder dominates the presentation.</p>
<p id="Par4">The International League Against Epilepsy recently consulted in an attempt to synthesise a consensus view [<xref ref-type="bibr" rid="CR6">6</xref>], whose output will be published in 2017. The result promises to be useful and pragmatic, recognizing that the syndromes are multifaceted; any one case defined by an association of clinical, electrophysiological, etiological and comorbid factors. It also accepts that it is not always known if seizures are part of focal or generalized epilepsy and that in some cases, such as tuberous sclerosis, genetic and structural causes overlap. Some terms will be dropped, for example, childhood epilepsies where the seizures remit will be called pharmacoresponsive rather than benign, recognizing that children whose seizures remit may nevertheless have significant persisting psychosocial comorbidities.</p>
<p id="Par5">The ILAE has also pondered the question of whether a single seizure may be considered to be epilepsy [<xref ref-type="bibr" rid="CR7">7</xref>] and concluded that it may if there is a greater than 60% chance of another seizure; a risk conferred by the presence of EEG spikes or a major structural aetiology. Epilepsy may be considered to have gone away after ten years with no seizures and with no treatment. This approach has pragmatic utility, rather than mechanistic validity and is useful in allowing driving regulatory authorities to treat those with lower risk more leniently and may be helpful in deciding when to treat medically after a single seizure [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
<p id="Par6">Some frontal lobe epilepsies may be particularly difficult to diagnose, often with non-diagnostic ictal scalp EEGs and some were initially considered to be a movement disorder, e.g. “paroxysmal nocturnal dystonia” [<xref ref-type="bibr" rid="CR9">9</xref>] in which its epileptic basis was shown later [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The situation has become more complex with the discovery that patients with frontal lobe epilepsy may also have epileptic nocturnal wandering, with similarities to parasomnias and also brief nocturnal movements which are not due to seizure discharges but may be a release phenomenon of interictal discharges [<xref ref-type="bibr" rid="CR11">11</xref>]. They may suffer also from non-epileptic parasomnias more frequently than the general population. In the new classification, the phenomenon will be renamed “Sleep-related hypermotor epilepsy (SHE)”.</p>
</sec>
<sec id="Sec2">
<title>Status epilepticus and limbic encephalitis</title>
<p id="Par7">The ILAE recently defined status epilepticus as: “a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point <italic>t</italic>
<sub>1</sub>). It is a condition, which can have long-term consequences (after time point <italic>t</italic>
<sub>2</sub>), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures” [<xref ref-type="bibr" rid="CR12">12</xref>]. Timepoint <italic>t</italic>
<sub>1</sub> is at 5 min after seizure onset, when it is recognized for generalized tonic–clonic status epilepticus that evolution to status is increasingly likely and when treatment should be initiated. T2 is at 30 min, after which there is increasing risk of irreversible consequences. Status is divided along four axes; semiology, aetiology, EEG correlates and age. These axes align with the prognosis of status, which when adequately treated is determined by cause and the age and gender of the patient. The electroclinical state is another prognosticator; subtle status evolving from convulsive status has a particularly poor prognosis [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p>
<p id="Par8">The impressive out-of-hospital randomized, double-blind RAMPART study has shown that IM midazolam is at least as effective as IV lorazepam in the early treatment of status, in adults and children [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], probably because IM speed of administration of midazolam compensates for speed of IV distribution of lorazepam. It has long been known that the effect of benzodiazepines in status epilepticus wears off very rapidly [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and it has subsequently been demonstrated that GABA<sub>A</sub> receptor sensitivity is reduced, sometimes long term [<xref ref-type="bibr" rid="CR18">18</xref>]. Receptor trafficking may be contributory [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. As well as a reduction in inhibitory neurotransmitters, within 1 h of onset of status in rats, there is an increase in surface NMDA receptors in status, associated with increased excitation [<xref ref-type="bibr" rid="CR21">21</xref>]. Cholinergic mechanisms are also implicated, supported by the observation that in pilocarpine induced status epilepticus; the addition of scopolamine provides additional seizure control, when combined with phenobarbital and benzodiazepines, raising the possibility of the use of drug combinations in status [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
<p id="Par9">Basic mechanisms are starting to align with clinical evidence in the initial treatment of status with benzodiazepines, but thereafter the evidence is less clear. Initial uncontrolled reports suggested a 70% success rate for the treatment of status epilepticus with levetiracetam [<xref ref-type="bibr" rid="CR23">23</xref>], but a recent randomized controlled trial of out-of-hospital clonazepam plus either levetiracetam or placebo was abandoned because of a lack of benefit in the levetiracetam arm [<xref ref-type="bibr" rid="CR24">24</xref>]. This mirrors the finding that diazepam plus phenytoin confers no additional benefit to lorazepam alone at 12 h [<xref ref-type="bibr" rid="CR14">14</xref>] and raises questions around the appropriate timing of the addition of AED to benzodiazepines. It also emphasizes the importance of properly controlled studies in an area where few have been undertaken. Shorvon et al. have undertaken meta-analyses of existing therapies [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR27">27</xref>]. From generally poor quality studies of lacosamide, levetiracetam, phenobarbital, phenytoin or valproate in benzodiazepine resistant status, they found efficacy ranging from 50% (phenytoin), to levetiracetam (68.5%), phenobarbital (58–84%) and valproate 76%. Lacosamide treatments were too few to give figures. The conclusion remains that all these drugs may be useful but there is no clear guidance on choice. The caution with which data from uncontrolled studies must be interpreted is highlighted by a recent randomized study of valproate versus phenobarbital which showed a 44% response to valproate and an 81% response to phenobarbital. However, in children, valproate may have fewer adverse effects and better efficacy than phenobarbital [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] and similar efficacy to phenytoin [<xref ref-type="bibr" rid="CR30">30</xref>]. But children may not be comparable to adults with a greater proportion of generalized epilepsies, more responsive to valproate. Future options include derivatives of valproate such as valnactomide and butylpropylacetamide, which may be more potently antiepileptic and less teratogenic in animal studies [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
<p id="Par10">For status epilepticus which remains refractory to a second line AED, a range of intravenous benzodiazepines or anaesthetic agents may be considered and again Shorvon et al. found that studies are of poor quality. They found that 35% of patients in these studies died and a further 13% had severe neurological deficits and 13% mild neurological deficits on recovery. Studies underway may help answer some of these questions [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Ketamine’s role in blocking NMDA receptors [<xref ref-type="bibr" rid="CR34">34</xref>] has led to it become increasingly popular in the treatment of refractory status, with some efficacy on the basis of uncontrolled retrospective series [<xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR37">37</xref>]. A randomized trial in children is planned [<xref ref-type="bibr" rid="CR38">38</xref>]. A recent trial of hypothermia showed no benefit at 90 days [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
<p id="Par11">It is increasingly recognized that some patients with refractory status epilepticus, where the cause was previously unrecognized, may be suffering from an antibody mediated encephalopathy, “limbic encephalitis”. Antibodies implicated include LGI1 and NMDA, with CASPR less associated with seizures [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. More recently, GABA<sub>B</sub> and AMPA receptors have been implicated in some cases [<xref ref-type="bibr" rid="CR42">42</xref>]. A specific phenotype of very brief, frequent and highly focal, faciobrachial dystonic seizures is almost pathognomonic of LGI1 associated disease, often heralding a more severe encephalopathy [<xref ref-type="bibr" rid="CR43">43</xref>] and providing an opportunity to intervene at an earlier stage. Limbic encephalitis exhibits characteristic changes on MRI in the mesial temporal structures, especially the amygdalae [<xref ref-type="bibr" rid="CR44">44</xref>] and responds primarily to immunotherapy and treatment of any associated tumour, rather than to AED [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Early suspicion of the diagnosis and treatment, even before definitive serological confirmation, is recommended. Many patients will recover with appropriate treatment but may be left with ongoing epilepsy and hippocampal sclerosis is a reported outcome [<xref ref-type="bibr" rid="CR46">46</xref>]. The extent to which epilepsy in patients, who have not suffered limbic encephalitis, may be attributable to antibody-mediated disease is an area of exploration which may open new avenues of treatment for chronic epilepsy. Small cohorts suggest increased rates of antibody positivity but their significance is not yet clear [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p>
</sec>
<sec id="Sec3">
<title>Pharmacological treatment of epilepsy and underlying mechanisms/genetics</title>
<p id="Par12">In 2000, Kwan and Brodie [<xref ref-type="bibr" rid="CR49">49</xref>] found that 63% of unselected patients in an epilepsy service were rendered seizure free with medication. Since then despite numerous antiepileptic drugs becoming available, they found that the chance of a patient, who is diagnosed in 2017 becoming seizure free, has changed little [<xref ref-type="bibr" rid="CR50">50</xref>]. Some studies are more optimistic; refractory epilepsy may have a greater chance of 12-month remission with or without AED change [<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR53">53</xref>] at around 5% per year and although up to 40% may relapse [<xref ref-type="bibr" rid="CR51">51</xref>], many of these may have a second longer remission.</p>
<p id="Par13">The broad sweep of AEDs, generally affecting ion channels or neurotransmitters is unchanged, but there is slowly increasing evidence for a differential effect in specific syndromes.</p>
<p id="Par14">Of established epilepsy drugs, ethosuximide, often forgotten by adult neurologists, has the most specific mechanism in relation to its role in the absence epilepsy. It acts on T-type calcium channels [<xref ref-type="bibr" rid="CR54">54</xref>], implicated in the thalamocortical disturbance believed for decades to underlie generalized epilepsies [<xref ref-type="bibr" rid="CR55">55</xref>]. Valproate and ethosuximide have clearly demonstrated greater efficacy over lamotrigine in childhood absence epilepsy [<xref ref-type="bibr" rid="CR56">56</xref>]. A small, non-randomized study has suggested that ethosuximide may be also associated with a greater chance of long-term remission [<xref ref-type="bibr" rid="CR57">57</xref>]. In a mouse model of absence epilepsy, Bomben et al. [<xref ref-type="bibr" rid="CR58">58</xref>] selectively ablated P/Q channels in the neurons of layer VI that provide the descending cortical projection to the thalamus. This produced spike-wave activity with clinical absences suppressed by ethosuximide. This very selective lesion supports the view that a highly specific cortical abnormality is necessary and sufficient to generate the thalamocortical oscillations of absence epilepsy. Not all patients respond equally to medication. A clinical imaging and EEG study, comparing those patients responsive to valproate to those who are resistant, suggested different patterns of activation may underlie the varying therapeutic responses [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
<p id="Par15">Despite strong epidemiological evidence of a genetic basis of IGE, relevant genes remain elusive, hampering efforts to identify specific drug targets. A recent genome wide association study suggested links to SCN1A, a known cause of GEFS+, protocadherin PCDH7 and PCDH19, both known to be associated with epilepsy and learning disability [<xref ref-type="bibr" rid="CR60">60</xref>]. An analysis of microdeletions in generalized epilepsy showed an increased burden (7.3%) compared to controls (4%) and specific involvement of a range of genes known to be important in epilepsy, psychiatry and neurodevelopment [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
<p id="Par16">The first major application of pharmacogenetics in epilepsy, and probably still the most widely applicable, has been the identification of patients from South East Asia who are HLA-B*1502 positive, putting them at high risk for Stevens–Johnson syndrome from carbamazepine and the elimination of this life-threatening complication by pre-treatment screening [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Genetic understanding is creeping into other areas of pharmacological therapeutics. It has been realized for a number of years that sodium channel blocking drugs may be deleterious for children with Dravet syndrome [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>], although this may not be so clear for adult patients [<xref ref-type="bibr" rid="CR66">66</xref>]. It is now known that Dravet syndrome is commonly due to a genetic truncations leading to total loss of function or missense mutations causing partial loss of function of the sodium channel, usually SCN1A [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>], which is located on inhibitory interneurons and causes hyperexcitability and seizures as a result of loss of function. A previously empirical observation of relative AED efficacy is now underpinned by a mechanistic understanding, which can guide drug choice. Mutations of the SCN8A gene are also associated with epilepsy, sometimes with a Dravet-like syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]. However, the phenotype may depend on the pathophysiology of the mutation, which may be a gain or a loss of function [<xref ref-type="bibr" rid="CR70">70</xref>]. In four children with epileptic encephalopathy onset in the first months of life, Boerma described a response to phenytoin [<xref ref-type="bibr" rid="CR71">71</xref>]. One of these had been demonstrated to have a gain of function mutation.</p>
<p id="Par17">There are a number of other instances where rare monogenic cases of epilepsy have been evaluated in detail and treatment tailored to the identified pathophysiological mechanism, with varying success. Most consistently effective is the use of ketogenic diet to switch cerebral energy metabolism away from glucose in patients with Glut-1 deficiency, which may be dramatically successful [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Retigabine (ezogabine) increases activity at KCNQ2 channels [<xref ref-type="bibr" rid="CR74">74</xref>] and has been used to treat the neonatal epileptic encephalopathy associated with reduced function mutations of the KCNQ2 channel with some success [<xref ref-type="bibr" rid="CR75">75</xref>]. Unfortunately, this drug is to be withdrawn from use in 2017 because of the pigmentary changes it may induce in skin, mucosae and eyes [<xref ref-type="bibr" rid="CR76">76</xref>]. GRIND2 mutations resulting in gain of activity of the NMDA receptor may cause balloon swelling and cell death. Children with a severe encephalopathy due to this mutation may possibly benefit from treatment with memantine, more generally used in Alzheimer’s disease which inhibits this channel [<xref ref-type="bibr" rid="CR77">77</xref>]. KCNT1 encodes a sodium-activated potassium channel and has been implicated in the migrating partial epilepsy of childhood and in autosomal dominant frontal lobe epilepsy, both causing a gain of function [<xref ref-type="bibr" rid="CR78">78</xref>]. Two children with this mutation and a severe epilepsy phenotype were helped by the administration of quinidine [<xref ref-type="bibr" rid="CR79">79</xref>]. These cases illustrate the importance of not only an electroclinical and genetic diagnosis of these epilepsies but also delineation of the specific pathophysiology of the mutation to enable drug choice, which may include opportunities beyond those conventionally used in the antiepileptic armamentarium.</p>
</sec>
<sec id="Sec4">
<title>Epileptogenesis and inflammation</title>
<p id="Par18">Another focus is the mechanisms of epileptogenesis; the process from initiation of pathological changes to the development of epilepsy and possibly the maintenance of epilepsy. There are changes, which involve altered gene expression, inflammation, protein production and changes in connectivity, which may all be the target for drugs to suppress epileptogenesis. One of the most studied pathways links to the rapamycin (mTOR) pathway (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Upregulation of mTOR, a serine/threonine protein kinase, occurs as a result of the TSC1 and TSC2 mutations of tuberous sclerosis (TS) complex. Other mutations in the pathway may be associated with overgrowth in megalencephaly [<xref ref-type="bibr" rid="CR80">80</xref>]. mTOR has a role in protein synthesis and inhibition of mTOR, cell growth and replication by everolimus, a rapamycin analogue, has been shown to reduce overgrowth of malignantly transformed tubers [<xref ref-type="bibr" rid="CR81">81</xref>]. Animal models have shown an antiepileptic effect of mTOR inhibition [<xref ref-type="bibr" rid="CR82">82</xref>] but this has been more difficult to demonstrate in humans. However, a recent double-blind study of 366 patients showed a dose-related seizure reduction of up to 40% with everolimus, in patients with TS [<xref ref-type="bibr" rid="CR83">83</xref>]. However, mTOR inhibitors may also have a direct effect on Kv1.1 ion channels, independent of epileptogenesis [<xref ref-type="bibr" rid="CR84">84</xref>], blurring their possible mechanism in seizure suppression.<fig id="Fig1"><label>Fig. 1</label><caption><p>Pathway showing some of the relationships between mTOR and cellular function which may be modulated in epileptogenesis and their modulation through inflammatory pathways and by drugs. <italic>AMPK</italic> 5′ AMP-activated protein kinase, <italic>IRS1</italic> insulin receptor substrate 1, <italic>JAK</italic> Janus kinase, <italic>MTOR</italic> mechanistic target of rapamycin, <italic>PDK1</italic> pyruvate dehydrogenase lipoamide kinase isozyme 1, <italic>P13K</italic> PI3 kinase, <italic>PKB</italic> protein kinase B, <italic>PtdIns</italic> phosphatidylinositol, <italic>PTEN</italic> phosphatase and tensin homologue, <italic>RHEB</italic> ras homolog enriched in brain (GTP binding protein), <italic>STRADA</italic> STE20-related kinase adaptor alpha, <italic>STK11</italic> serine/threonine kinase 11, <italic>TSC</italic> tuberous sclerosis complex</p></caption><graphic id="MO1" xlink:href="415_2017_8394_Fig1_HTML"></graphic></fig>
</p>
<p id="Par19">Whilst immunological mechanisms are clearly implicated in the aetiology of certain epilepsies such as limbic encephalitis [<xref ref-type="bibr" rid="CR85">85</xref>] or Rasmussen encephalitis [<xref ref-type="bibr" rid="CR86">86</xref>], increasing attention has been given to them in commoner forms of epilepsy. There is broad evidence for their significance, especially from animal studies and involving cytokines, changes in the blood brain barrier and pathological alterations associated with altered excitability [<xref ref-type="bibr" rid="CR87">87</xref>–<xref ref-type="bibr" rid="CR94">94</xref>]. Pathological examination of resected human specimens of focal cortical dysplasia [<xref ref-type="bibr" rid="CR95">95</xref>] has also shown substantial increases in mRNA expression of Toll-like receptors 2 and 4 and associated with high-mobility group box protein 1, restricted to astrocytes and microglia in pathological tissue. These interact through interleukin IL1-β. Microglia activation appears increased more in focal cortical dysplasia (FCD) type II than in FCD I, associated with the migration of activated lymphocytes and activation of the mTOR pathway, linking inflammation to epileptogenesis [<xref ref-type="bibr" rid="CR96">96</xref>]. A recent systematic review and meta-analysis [<xref ref-type="bibr" rid="CR97">97</xref>] has described increased CNS levels of interleukins of the IL1 family as well as of chemocytokines CCL 3-5, which are involved in monocyte and lymphocyte migration. IL6 appears to be elevated in serum but not in CNS. A recent study of patients with moderate to severe cerebral trauma found a relationship between cerebrospinal fluid IL1-β levels and an allelic variant of the IL1-β gene to the risk of developing epilepsy [<xref ref-type="bibr" rid="CR98">98</xref>]. This provides the first evidence of a biomarker that might be used to predict epilepsy after an epileptogenic insult and possibly a means of pharmacological intervention. These may need to be complex; a recent study suggested a single intervention was inadequate and a cocktail of anti-inflammatory drugs was required to prevent epileptogenesis [<xref ref-type="bibr" rid="CR99">99</xref>]. A small case series of intractable childhood onset epilepsy has already been treated successfully with human recombinant IL-1 receptor antagonist (Anakinra\) [<xref ref-type="bibr" rid="CR100">100</xref>] and it is hopeful that, as there are already many drugs affecting the immune system and some affecting the blood brain barrier, that this will prove a fertile area for development.</p>
<p id="Par20">Recently, mutations of the DEPDC5 (DEP domain containing 5, involved in g-protein signalling) gene have been demonstrated in patients with cortical dysplasia and in up to 12% of small families of patients with familial focal epilepsy phenotypes, including ADNFLE without demonstrable lesions [<xref ref-type="bibr" rid="CR101">101</xref>–<xref ref-type="bibr" rid="CR103">103</xref>]. This gene is involved in the same GATOR pathway as mTOR. Although the GATOR (gap activity towards RAG’s) pathway is generally associated with protein synthesis, it appears to reduce the levels of K<sub>v</sub>1.1 potassium channels in hippocampal pyramidal neurons increasing seizure expression, which can be reversed by inhibitors [<xref ref-type="bibr" rid="CR104">104</xref>]. These findings link lesional and non-lesional ion channel related epilepsies to the same pathway, providing a potential opportunity for the wider use of inhibitors in treatment.</p>
<p id="Par21">Although the scope is expanding, the relationship of these mechanisms to the majority of epilepsies, those triggered by a neurological insult (focal epilepsies) or a complex genetic trait (generalized epilepsies) remains to be established. It has long been recognized that epilepsy due to trauma is more likely in those with a family history of epilepsy [<xref ref-type="bibr" rid="CR105">105</xref>] providing a potential to link to genetic mechanisms. But the development of epilepsy may take 20 years [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. The key will be to identify those patients at high risk and to find a low risk preventative treatment akin to aspirin in stroke and very large, long-term follow up studies, will be needed to establish efficacy. Biomarkers such as IL1-β for evolving epileptogenesis are needed to identify high risk patients and to act as drug targets.</p>
</sec>
<sec id="Sec5">
<title>Antiepileptic drug trials</title>
<p id="Par22">Despite being a common disorder, the number of high quality trials of antiepileptic drugs is small. Trials of new AED are normally in the form of an add-on therapy in refractory partial epilepsy, usually with the end point of a 50% reduction of seizures. This may be realistic in showing a biological effect but does not confer the psychosocial benefits of seizure freedom, and therefore drugs enter the market with the knowledge that they will not dramatically alter the burden of refractory epilepsy. The Federal Drug Administration in the US requires monotherapy trials against placebo and the European Medicines Agency requires head-to-head trial of active agents. Consequently, results cannot cross the Atlantic, delaying introduction and increasing cost for manufacturers. Both types of trials have their merits. The result is a non-systematic hotchpotch of evidence in relation to monotherapy in epilepsy. Whilst the pragmatic study SANAD has guided many UK clinicians to lamotrigine as first line in monotherapy for focal epilepsy [<xref ref-type="bibr" rid="CR107">107</xref>], carbamazepine remains a drug of choice in many countries and studies [<xref ref-type="bibr" rid="CR108">108</xref>]. A recent study has shown that zonisamide is non-inferior to carbamazepine in new onset focal epilepsy in adults [<xref ref-type="bibr" rid="CR109">109</xref>]. A large study of 1688 new onset patients compared time to withdrawal of levetiracetam in two arms to first choice carbamazepine or valproate in monotherapy in adults [<xref ref-type="bibr" rid="CR110">110</xref>]. Overall, the drugs performed similarly but in a post hoc analysis, levetiracetam withdrawal rate was lower in those over 60, especially in comparison to carbamazepine, with fewer adverse effects rather than greater efficacy [<xref ref-type="bibr" rid="CR111">111</xref>].</p>
<p id="Par23">The repertoire of AED considered effective in IGE has traditionally been more restricted that for focal epilepsy. Case reports have supported the use of lacosamide [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>] and it is the subject of ongoing larger scale studies. Perampanel has been found to be effective as an add-on for refractory generalized epilepsy with tonic–clonic seizures [<xref ref-type="bibr" rid="CR114">114</xref>].</p>
<p id="Par24">Cannabis contains approximately 80 different active cannabinoids and was used in the nineteenth century as an AED [<xref ref-type="bibr" rid="CR115">115</xref>]. It has been known for many years to be an antagonist at NMDA receptors with antiepileptic activity [<xref ref-type="bibr" rid="CR116">116</xref>]. Δ<sup>9</sup> tetrahydrocannabinol is the main psychoactive component of cannabis, acting on THC1 and THC2 receptors but other components, especially cannabidiol (CBD) do not act on these receptors, are not psychoactive. They may have medicinal properties through a range of other actions [<xref ref-type="bibr" rid="CR117">117</xref>]. Clinical studies in the 1970s and 80s reviewed in [<xref ref-type="bibr" rid="CR117">117</xref>] pointed to antiepileptic effects and recent anecdotal evidence and an open labelled trial have shown benefit in epileptic encephalopathies such as Dravet syndrome [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>], which have had a profound social effect in the United States, with parents moving their families to states where cannabis is legal [<xref ref-type="bibr" rid="CR120">120</xref>]. Although their mechanisms point to a potential role for cannabinoids of relevance to epilepsy [<xref ref-type="bibr" rid="CR121">121</xref>], there are as yet, no good studies to support their widespread use. The adverse effects of natural cannabis are widely known [<xref ref-type="bibr" rid="CR122">122</xref>] and a particular problem for adolescents. Cannabinoids should be avoided by those with epilepsy, especially the young, who are already at risk of psychiatric problems, until good quality trials support their use.</p>
</sec>
<sec id="Sec6">
<title>Epilepsy and comorbid depression</title>
<p id="Par25">Data extracted from a US population survey of 340,000 households and those with epilepsy were compared to those without [<xref ref-type="bibr" rid="CR123">123</xref>]. Two percent had suffered with epilepsy and reported increases in a range of disorders (Table <xref ref-type="table" rid="Tab1">1</xref>). A figure of approximately one third affected by depression is consistent with numerous previous studies. The relationship to epilepsy is complex. In studies of IGE, the epilepsy and its impact may be important [<xref ref-type="bibr" rid="CR124">124</xref>] but there is often dissociation between a good seizure outcome and a poor psychosocial outcome [<xref ref-type="bibr" rid="CR125">125</xref>]. A key factor predicting outcome relates to family environment support [<xref ref-type="bibr" rid="CR126">126</xref>] but a biological association is supported by the observation that children and adults have an increased risk of psychiatric disturbance, even before the onset of their epilepsy [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>], and by a broad range of experimental studies [<xref ref-type="bibr" rid="CR129">129</xref>]. Interactions between epilepsy and depression may include shared abnormalities in a number of neurotransmitters including 5HT<sub>1A</sub> mechanisms [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>] and via glutamate, where low-dose ketamine, an antiepileptic NMDA antagonist, may have an impact on depression [<xref ref-type="bibr" rid="CR132">132</xref>]. These studies illustrate a bidirectional relationship of epilepsy and depression, involving both biological and psychosocial factors.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comorbidities in a nationwide US survey [<xref ref-type="bibr" rid="CR123">123</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"></th><th align="left">No epilepsy (%)</th><th align="left">Epilepsy (%)</th></tr></thead><tbody><tr><td align="left">Anxiety</td><td align="char" char=".">13.9</td><td align="char" char=".">22.4</td></tr><tr><td align="left">Depression</td><td align="char" char=".">25.6</td><td align="char" char=".">32.5</td></tr><tr><td align="left">Bipolar disorder</td><td align="char" char=".">6.7</td><td align="char" char=".">14.1</td></tr><tr><td align="left">ADHD</td><td align="char" char=".">5.5</td><td align="char" char=".">13.2</td></tr><tr><td align="left">Sleep disorder/apnea</td><td align="char" char=".">13.6</td><td align="char" char=".">19.6</td></tr><tr><td align="left">Movement disorder/tremor</td><td align="char" char=".">4.6</td><td align="char" char=".">9.3</td></tr><tr><td align="left">Migraine</td><td align="char" char=".">20.6</td><td align="char" char=".">27.9</td></tr><tr><td align="left">Chronic pain</td><td align="char" char=".">17.7</td><td align="char" char=".">25.4</td></tr><tr><td align="left">Fibromyalgia</td><td align="char" char=".">7.5</td><td align="char" char=".">15.4</td></tr><tr><td align="left">Neuropathic pain</td><td align="char" char=".">5.6</td><td align="char" char=".">8.7</td></tr><tr><td align="left">Asthma</td><td align="char" char=".">16.6</td><td align="char" char=".">20.7</td></tr><tr><td align="left">Diabetes</td><td align="char" char=".">15.2</td><td align="char" char=".">15.2</td></tr><tr><td align="left">Hypertension</td><td align="char" char=".">36.7</td><td align="char" char=".">36.2</td></tr></tbody></table></table-wrap>
</p>
<p id="Par26">A common concern is that antidepressants may increase seizures. The risk of <italic>de novo</italic> seizures from the use antidepressants is 0.1% for newer drugs and 0.3% from older drugs, e.g. tricyclics [<xref ref-type="bibr" rid="CR133">133</xref>]. Exceptions may be maprotiline, bupropion or clomipramine with a higher risk [<xref ref-type="bibr" rid="CR134">134</xref>] but overall, those in the treatment arm of antidepressant trials had fewer seizures than those in the placebo arms [<xref ref-type="bibr" rid="CR134">134</xref>]. In smaller studies of those with epilepsy at therapeutic doses of antidepressants, many will experience an improvement in their epilepsy [<xref ref-type="bibr" rid="CR135">135</xref>]. A recent review has brought together the newer mechanistic evidence, showing that 5HT<sub>1A</sub> may mediate a number of actions, which have antiepileptic effects, including increasing GABA activity and reducing inflammatory cytokines and those patients with epilepsy may have reduced PET ligand binding at 5 HT<sub>1A</sub> sites [<xref ref-type="bibr" rid="CR136">136</xref>]. In a mouse model of sudden unexplained death in epilepsy, drugs acting on 5-HT<sub>3</sub> receptors (fluoxetine, blocked by ondansetron) reduced respiratory arrest in seizures, without affecting the seizures themselves [<xref ref-type="bibr" rid="CR137">137</xref>], a further possible mode of benefit of antidepressants in epilepsy. Where possible, it may be appropriate to avoid those antidepressants with pharmacokinetic interactions with AED, such as fluvoxamine, paroxetine and fluoxetine. Hopefully, neurologists can now encourage the use of antidepressants, especially as psychiatric comorbidity is a greater determinant of quality of life than seizure frequency in those with refractory epilepsy [<xref ref-type="bibr" rid="CR138">138</xref>].</p>
</sec>
<sec id="Sec7">
<title>Antiepileptic drugs and pregnancy</title>
<p id="Par27">In recent years, information regarding major congenital malformation (MCM) rates has been consolidated in epilepsy and pregnancy registries. AED are divided into those with reasonably quantified risk and those with insufficient data. This becomes self-reinforcing with increased reluctance to prescribe drugs of uncertain risk to those who may conceive. The most recent data from the UK epilepsy and pregnancy register, shows a very clear dose-related effect with valproate risk 5% with &lt;600 mg daily increasing to 11% at over 1000 mg. Carbamazepine at 2% risk when given at &lt;500 mg daily, 3% at 500–1000 mg and 5% at &gt;1000 mg. Lamotrigine had a less steep curve with 2% at &lt;200 mg, increasing to 3.5% over 400 mg daily [<xref ref-type="bibr" rid="CR139">139</xref>]. These data are similar to those published from European and US registries [<xref ref-type="bibr" rid="CR140">140</xref>]. Oxcarbazepine, not widely used in the UK, appears to have similar low risk to lamotrigine at 2.2% [<xref ref-type="bibr" rid="CR141">141</xref>]. The risk for levetiracetam appears similarly low at 0.7% in monotherapy, increasing in polytherapy [<xref ref-type="bibr" rid="CR142">142</xref>]. Added to the risk of MCM are concerns over more subtle neurodevelopmental disturbances, including lower IQ, autism and ADHD, which may conceivably arise from exposure to valproate at any stage of pregnancy [<xref ref-type="bibr" rid="CR143">143</xref>–<xref ref-type="bibr" rid="CR146">146</xref>]. Although not widely used in pregnant women, topiramate and zonisamide may be associated with significantly lower birthweight [<xref ref-type="bibr" rid="CR147">147</xref>]. Recent data have also shown the importance of considering genetic factors in teratogenicity. A family history of abnormalities increases the risk. The risk to a second child, where a first was affected by an AED may be as high as 17–36% [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>]. Clinicians must also consider the risk to the mother of epilepsy in pregnancy and data suggest a tenfold increase in mortality compared to non-epilepsy controls, largely due to SUDEP [<xref ref-type="bibr" rid="CR150">150</xref>].</p>
</sec>
<sec id="Sec8">
<title>Epilepsy surgery</title>
<p id="Par28">Given the low chance of response to medical therapy after the failure of two AED [<xref ref-type="bibr" rid="CR49">49</xref>], this is the widely accepted yardstick for defining refractoriness and the appropriateness for consideration of resective epilepsy surgery. The proportion of patients for whom surgery may be successful is not clear, but is estimated as a maximum of around 2% of the total cohort. With an incidence of 0.5%, in the USA and a prevalence of 750,000, this translates to up to 3500 incident cases and 15,000 prevalent cases, in which surgery might be considered. The rate of epilepsy surgery has remained static at around 1500 cases per year [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>] for over 20 years. The pattern of cases operated may be changing with a reduction in mesial temporal sclerosis [<xref ref-type="bibr" rid="CR153">153</xref>], perhaps due to improved outcomes of childhood febrile seizures. At the same time, the outcomes of extratemporal epilepsies are improving with new diagnostic techniques. The mortality of surgery is around 0.1–0.5% [<xref ref-type="bibr" rid="CR151">151</xref>], similar to the annual rate of SUDEP in refractory epilepsy [<xref ref-type="bibr" rid="CR154">154</xref>], i.e. the mortality of ongoing refractory epilepsy exceeds the post-operative risk after one year. Complication rates have reduced [<xref ref-type="bibr" rid="CR155">155</xref>] and are around 3% for major and 7% for minor complications; one of the commonest complications is a visual field defect after temporal lobectomy [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. The treatment is cost-effective in the long term, with sustained remission and close to half of adult patients and 86% of children may be able to stop their AEDs. Two recent studies have found risk factors for seizure recurrence after post-operative drug withdrawal included pre-operative seizure frequency and post-operative EEG abnormalities [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR158">158</xref>]. They also found about one third of those relapsing will not come back under control with re-introduction of medication, especially those with early recurrence, perhaps reflecting a less complete surgical remission.</p>
<p id="Par29">Health-related quality of life often returns to normal in those who become seizure free [<xref ref-type="bibr" rid="CR159">159</xref>]. Negative prognostic factors include high seizure frequency and long duration at baseline [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. Those with lesions such as cavernomas or benign tumours may achieve 77% seizure freedom at two years, even if surgery is undertaken after a long seizure history [<xref ref-type="bibr" rid="CR162">162</xref>].</p>
<p id="Par30">Advances in epilepsy surgery include alternative methods to resective surgery; improvements in techniques of case selection for surgery and neurostimulation techniques.</p>
<p id="Par31">Radiosurgery for arteriovenous malformations may give excellent outcomes for associated epilepsy and positive prognostic factors have been reported to be presentation with haemorrhage rather than epilepsy and the absence of post-treatment haemorrhage [<xref ref-type="bibr" rid="CR163">163</xref>–<xref ref-type="bibr" rid="CR165">165</xref>]. A recent meta-analysis of stereotactic radiosurgery for mesial temporal sclerosis [<xref ref-type="bibr" rid="CR166">166</xref>] showed that the total number of patients reported remains low (&lt;200) but that half became seizure free at a median of 14 months after treatment with a complication rate of around 8% (excluding headache which was more common) and rates of visual field defects similar to open surgery. MRI-guided laser thermocoagulation has been undertaken in a few patient with initially promising results. Procedural morbidity is low and patients may be admitted for just one day. It has been suggested as appropriate particularly for older patients. [<xref ref-type="bibr" rid="CR167">167</xref>–<xref ref-type="bibr" rid="CR170">170</xref>]. The electrodes inserted for stereotactic EEG recording may also be used to deliver a thermocoagulation induced lesion to the surrounding brain, with a diameter of 4.5–7 mm. This has been undertaken in patients with hypothalamic hamartoma, for whom surgery is difficult and with a high success in remission of the gelastic seizures associated with these lesions [<xref ref-type="bibr" rid="CR171">171</xref>]. Early indications are that this may be an approach which can be undertaken in cases of focal cortical dysplasia.</p>
<p id="Par32">The identification of patients who will benefit from epilepsy surgery relies on the demonstration of a single brain region responsible for the epilepsy, which can be safely resectable. Identification of a responsible lesion has been demonstrated in numerous studies to predict a better outcome [<xref ref-type="bibr" rid="CR172">172</xref>]. Even in those where imaging is normal, resection on the basis of an intracranial EEG abnormality is more likely to result in seizure freedom if the resected tissue is pathologically abnormal [<xref ref-type="bibr" rid="CR173">173</xref>]. Increasing pre-operative identification of pathology through improved MRI, through higher field strengths up to 7 T in vivo and enhancing 3 T with automated measures of hippocampal volumes potentially gives a greater chance of identifying candidates who may benefit from surgery [<xref ref-type="bibr" rid="CR174">174</xref>–<xref ref-type="bibr" rid="CR176">176</xref>]. In those whom structural imaging remains negative, then FDG-PET can aid in the decision making, either in favour of surgery, e.g. in those thought to have non-dominant TLE or against surgery in more complex cases [<xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]. Magnetoencephalography is not widely used [<xref ref-type="bibr" rid="CR179">179</xref>], but a recent study demonstrated that if all MEG abnormal areas were resected, prognosis was improved and MEG can be used to target SEEG more successfully [<xref ref-type="bibr" rid="CR180">180</xref>]. Tight clustering of MEG abnormalities predicted a better outcome than more dispersed abnormalities. High density EEG source imaging using increased electrode number may also be valuable in predicting the outcome of surgery [<xref ref-type="bibr" rid="CR181">181</xref>]. Intravascular stent EEG, shown to be safe in sheep may be a non-invasive method of intracranial EEG recording in the future [<xref ref-type="bibr" rid="CR182">182</xref>].</p>
<p id="Par33">Where resective surgery is not possible, palliative stimulation techniques may be considered. The most established and widely used is vagus nerve stimulation which is safe, with a low risk of complications, such as infection, haematoma and vocal cord palsy [<xref ref-type="bibr" rid="CR183">183</xref>]. An analysis from the VNS registry combined with pooled study data totaling 8423 patients [<xref ref-type="bibr" rid="CR184">184</xref>] found that responder rate, defined by a 50% seizure reduction, was 47% at 0–14 months and 63% at 24–48 months with seizure free rates rising from 5–10% over the same period. Quality of life measures also improved with VNS [<xref ref-type="bibr" rid="CR185">185</xref>], which may relate to seizure reduction, reduced AED load in association with successful antiepileptic treatment or putative effects of VNS on mood [<xref ref-type="bibr" rid="CR186">186</xref>]. Responsive stimulation involves a closed circuit of intracranial electrodes with electrical stimuli delivered to the brain according to a seizure detection paradigm. The circuit is often installed following electrode placement in an unsuccessful attempt to identify a surgical target. In 191 patients there was a 37.9% responder rate compared to 17.3% in the sham group. [<xref ref-type="bibr" rid="CR187">187</xref>]. Electrodes placed in the thalamus have been associated with a 69% median reduction in seizure frequency and a 35% rate of serious adverse events, including infection in 10% and lead misplacement in 8% [<xref ref-type="bibr" rid="CR188">188</xref>]. Other targets under investigation include the nucleus accumbens [<xref ref-type="bibr" rid="CR189">189</xref>] and the cerebellum [<xref ref-type="bibr" rid="CR190">190</xref>]. Optogenetic methods [<xref ref-type="bibr" rid="CR191">191</xref>], successful in animals, have not yet been applied in humans.</p>
</sec>
<sec id="Sec9">
<title>Summary</title>
<p id="Par34">A new classification of epilepsies will support the integration of novel aetiological and genetic factors with the existing electroclinical classification and help identify when a single seizure might be considered epilepsy on the basis of an abnormal EEG or imaging. Midazolam IM has emerged as the benzodiazepine of choice in out-of-hospital treatment of status epilepticus and a valid alternative in hospital, but good clinical studies are lacking beyond this early stage. Limbic encephalitis is increasingly diagnosed and primary treatment is immunotherapy rather than AED. The significance of antibodies more generally in epilepsy remains unclear. Most epilepsy treatment remains without a clear evidence base but ethosuximide and valproate have been demonstrated to be the most efficacious AED in absence epilepsy. Perampanel and lacosamide are new drugs which are emerging as treatments for tonic–clonic seizures in generalized epilepsy. A small number of specific genetic epilepsies have allowed personalized treatment in specific cases but this has not yet had broader application. Epileptogenesis is a fertile area of research and everolimus, an inhibitor of the mTor pathway, has demonstrated efficacy in epilepsy associated with TS, showing the clinical potential of this avenue of research for the first time. Epilepsy and pregnancy registers are consolidating data pointing to the use of lamotrigine, levetiracetam, carbamazepine and/or oxcarbazepine as those AED with the lowest risk of major congenital malformations. New evidence has associated topiramate and zonisamide with low birth weight. Clinicians can treat comorbid depression with most modern antidepressants, reassured that there is little evidence of an adverse effect on their patient’s epilepsy. Surgical treatment of epilepsy remains under-utilised and the selection of patients for surgical treatment of epilepsy is becoming more refined with the use of functional imaging to support structural imaging. Alternative ablative treatments are being explored but are not yet widespread. Stimulation techniques other than VNS are areas of research, which remain to find their place.</p>
<p id="Par35">Overall, recent epilepsy research has started to change our thinking and approach to patients, as we slowly move towards a more rational basis by which to treat this common condition.</p>
</sec>
</body>
<back>
<notes notes-type="COI-statement">
<title>Compliance with ethical standards</title>
<sec id="FPar1">
<title>Conflicts of interest</title>
<p id="Par36">Dr. Manford has no conflicts of interest.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gastaut</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Caveness</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Landolt</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A proposed international classification of epileptic seizures</article-title>
<source/>Epilepsia
          <year>1964</year>
<volume>5</volume>
<fpage>297</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1964.tb03332.x</pub-id>
<pub-id pub-id-type="pmid">14273591</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merlis</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Proposal for an international classification of the epilepsies</article-title>
<source/>Epilepsia
          <year>1970</year>
<volume>11</volume>
<fpage>114</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1970.tb03873.x</pub-id>
<pub-id pub-id-type="pmid">5268245</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Commission on Classification and Terminology of the International League Against Epilepsy</collab>
</person-group>
<article-title>Proposal for revised clinical and electroencephalographic classification of epileptic seizures</article-title>
<source/>Epilepsia
          <year>1981</year>
<volume>22</volume>
<fpage>489</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1981.tb06159.x</pub-id>
<pub-id pub-id-type="pmid">6790275</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology</article-title>
<source/>Epilepsia
          <year>2001</year>
<volume>42</volume>
<fpage>796</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1046/j.1528-1157.2001.10401.x</pub-id>
<pub-id pub-id-type="pmid">11422340</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<fpage>676</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02522.x</pub-id>
<pub-id pub-id-type="pmid">20196795</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Classification of the epilepsies: new concepts for discussion and debate-special report of the ILAE Classification Task Force of the Commission for Classification and Terminology</article-title>
<source/>Epilepsia Open
          <year>2016</year>
<volume>1</volume>
<fpage>37</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1002/epi4.5</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Acevedo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Arzimanoglou</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ILAE official report: a practical clinical definition of epilepsy</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>475</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12550</pub-id>
<pub-id pub-id-type="pmid">24730690</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krumholz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wiebe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gronseth</surname>
<given-names>GS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence-based guideline: management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<fpage>1705</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000001487</pub-id>
<pub-id pub-id-type="pmid">25901057</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lugaresi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cirignotta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Montagna</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Nocturnal paroxysmal dystonia</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1986</year>
<volume>49</volume>
<fpage>375</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.49.4.375</pub-id>
<pub-id pub-id-type="pmid">2939199</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tinuper</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cerullo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cirignotta</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nocturnal paroxysmal dystonia with short-lasting attacks: three cases with evidence for an epileptic frontal lobe origin of seizures</article-title>
<source/>Epilepsia
          <year>1990</year>
<volume>31</volume>
<fpage>549</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1990.tb06105.x</pub-id>
<pub-id pub-id-type="pmid">2401246</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parrino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Halasz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tassinari</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Terzano</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>CAP, epilepsy and motor events during sleep: the unifying role of arousal</article-title>
<source/>Sleep Med Rev
          <year>2006</year>
<volume>10</volume>
<fpage>267</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="doi">10.1016/j.smrv.2005.12.004</pub-id>
<pub-id pub-id-type="pmid">16809057</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cock</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hesdorffer</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A definition and classification of status epilepticus: report of the ILAE task force on classification of status epilepticus</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>1515</fpage>
<lpage>1523</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13121</pub-id>
<pub-id pub-id-type="pmid">26336950</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Treiman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>NY</given-names>
</name>
<name>
<surname>Kendrick</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus</article-title>
<source/>Epilepsy Res
          <year>1990</year>
<volume>5</volume>
<fpage>49</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/0920-1211(90)90065-4</pub-id>
<pub-id pub-id-type="pmid">2303022</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Treiman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Meyers</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>NY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A comparison of four treatments for generalized convulsive status epilepticus</article-title>
<source/>N Engl J Med
          <year>1998</year>
<volume>339</volume>
<fpage>792</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199809173391202</pub-id>
<pub-id pub-id-type="pmid">9738086</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welch</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Durkalski-Mauldin</surname>
<given-names>VL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>254</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12905</pub-id>
<pub-id pub-id-type="pmid">25597369</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silbergleit</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Durkalski</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lowenstein</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intramuscular versus intravenous therapy for prehospital status epilepticus</article-title>
<source/>N Engl J Med
          <year>2012</year>
<volume>366</volume>
<fpage>591</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1107494</pub-id>
<pub-id pub-id-type="pmid">22335736</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapur</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Rapid seizure-induced reduction of benzodiazepine and Zn <sup>2+</sup> sensitivity of hippocampal dentate granule cell GABA A receptors</article-title>
<source/>J Neurosci
          <year>1997</year>
<volume>17</volume>
<fpage>7532</fpage>
<lpage>7540</lpage>
<pub-id pub-id-type="pmid">9295398</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapur</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stringer</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lothman</surname>
<given-names>EW</given-names>
</name>
</person-group>
<article-title>Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition</article-title>
<source/>J Neurophysiol
          <year>1989</year>
<volume>61</volume>
<fpage>417</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="pmid">2918363</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodkin</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mtchedlishvili</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Subunit-specific trafficking of GABA(A) receptors during status epilepticus</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>2527</fpage>
<lpage>2538</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3426-07.2008</pub-id>
<pub-id pub-id-type="pmid">18322097</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naylor</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>7724</fpage>
<lpage>7733</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4944-04.2005</pub-id>
<pub-id pub-id-type="pmid">16120773</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naylor</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Niquet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wasterlain</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus</article-title>
<source/>Neurobiol Dis
          <year>2013</year>
<volume>54</volume>
<fpage>225</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2012.12.015</pub-id>
<pub-id pub-id-type="pmid">23313318</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Löscher</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Single versus combinatorial therapies in status epilepticus: novel data from preclinical models</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>49</volume>
<fpage>20</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.02.027</pub-id>
<pub-id pub-id-type="pmid">25819944</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinka</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>What is the evidence to use new intravenous AEDs in status epilepticus?</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<fpage>35</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03232.x</pub-id>
<pub-id pub-id-type="pmid">21967358</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dagron</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Elie</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial</article-title>
<source/>Lancet Neurol
          <year>2016</year>
<volume>15</volume>
<fpage>47</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00296-3</pub-id>
<pub-id pub-id-type="pmid">26627366</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shorvon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ferlisi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol</article-title>
<source/>Brain
          <year>2011</year>
<volume>134</volume>
<fpage>2802</fpage>
<lpage>2818</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awr215</pub-id>
<pub-id pub-id-type="pmid">21914716</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shorvon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ferlisi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy</article-title>
<source/>Brain
          <year>2012</year>
<volume>135</volume>
<fpage>2314</fpage>
<lpage>2328</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aws091</pub-id>
<pub-id pub-id-type="pmid">22577217</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasiry</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shorvon</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies</article-title>
<source/>Seizure
          <year>2014</year>
<volume>23</volume>
<fpage>167</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2013.12.007</pub-id>
<pub-id pub-id-type="pmid">24433665</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malamiri</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Ghaempanah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khosroshahi</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial</article-title>
<source/>Eur J Paediatr Neurol
          <year>2012</year>
<volume>16</volume>
<fpage>536</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2012.01.012</pub-id>
<pub-id pub-id-type="pmid">22326977</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenobarbital versus valproate for generalized convulsive status epilepticus in adults: a prospective randomized controlled trial in China</article-title>
<source/>CNS Drugs
          <year>2016</year>
<volume>30</volume>
<fpage>1201</fpage>
<lpage>1207</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-016-0388-6</pub-id>
<pub-id pub-id-type="pmid">27878767</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vardhan Gupta</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chawla</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>comparative assessment for the efficacy of valproate and phenytoin for controlling seizures in patients of convulsive status epilepticus: a randomized controlled trial</article-title>
<source/>J Adv Med Dent Sci Res
          <year>2015</year>
<volume>3</volume>
<fpage>S15</fpage>
<lpage>S20</lpage>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shekh-Ahmad</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mawasi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McDonough</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>49</volume>
<fpage>298</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.04.012</pub-id>
<pub-id pub-id-type="pmid">25979572</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleck</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cock</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The established status epilepticus trial 2013</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>89</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12288</pub-id>
<pub-id pub-id-type="pmid">24001084</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legriel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pico</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tran-Dinh</surname>
<given-names>Y-R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS</article-title>
<source/>Ann Intensiv Care
          <year>2016</year>
<volume>6</volume>
<fpage>54</fpage>
<pub-id pub-id-type="doi">10.1186/s13613-016-0159-z</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Glasgow</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Povysheva</surname>
<given-names>NV</given-names>
</name>
</person-group>
<article-title>Recent insights into the mode of action of memantine and ketamine</article-title>
<source/>Curr Opin Pharmacol
          <year>2015</year>
<volume>20</volume>
<fpage>54</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2014.11.006</pub-id>
<pub-id pub-id-type="pmid">25462293</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Synowiec</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Yenugadhati</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ketamine use in the treatment of refractory status epilepticus</article-title>
<source/>Epilepsy Res
          <year>2013</year>
<volume>105</volume>
<fpage>183</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2013.01.007</pub-id>
<pub-id pub-id-type="pmid">23369676</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoefler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rohracher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kalss</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study</article-title>
<source/>CNS Drugs
          <year>2016</year>
<volume>30</volume>
<fpage>869</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-016-0371-2</pub-id>
<pub-id pub-id-type="pmid">27465262</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaspard</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Judd</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>1498</fpage>
<lpage>1503</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12247</pub-id>
<pub-id pub-id-type="pmid">23758557</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ilvento</surname>
<given-names>L</given-names>
</name>
<name>
<surname>L’Erario</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01)</article-title>
<source/>BMJ Open
          <year>2016</year>
<volume>6</volume>
<fpage>e011565</fpage>
<pub-id pub-id-type="doi">10.1136/bmjopen-2016-011565</pub-id>
<pub-id pub-id-type="pmid">27311915</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legriel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lemiale</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schenck</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypothermia for neuroprotection in convulsive status epilepticus</article-title>
<source/>N Engl J Med
          <year>2016</year>
<volume>375</volume>
<fpage>2457</fpage>
<lpage>2467</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1608193</pub-id>
<pub-id pub-id-type="pmid">28002714</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irani</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia</article-title>
<source/>Brain
          <year>2010</year>
<volume>133</volume>
<fpage>2734</fpage>
<lpage>2748</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awq213</pub-id>
<pub-id pub-id-type="pmid">20663977</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Titulaer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gabilondo</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study</article-title>
<source/>Lancet Neurol
          <year>2013</year>
<volume>12</volume>
<fpage>157</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70310-1</pub-id>
<pub-id pub-id-type="pmid">23290630</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dogan Onugoren</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Deuretzbacher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haensch</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2015</year>
<volume>86</volume>
<fpage>965</fpage>
<lpage>972</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2014-308814</pub-id>
<pub-id pub-id-type="pmid">25300449</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irani</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Michell</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis</article-title>
<source/>Ann Neurol
          <year>2011</year>
<volume>69</volume>
<fpage>892</fpage>
<lpage>900</lpage>
<pub-id pub-id-type="doi">10.1002/ana.22307</pub-id>
<pub-id pub-id-type="pmid">21416487</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schoene-Bake</surname>
<given-names>J-C</given-names>
</name>
<name>
<surname>Malter</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantitative FLAIR analysis indicates predominant affection of the amygdala in antibody-associated limbic encephalitis</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>1679</fpage>
<lpage>1687</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12320</pub-id>
<pub-id pub-id-type="pmid">23889589</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irani</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Stagg</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype</article-title>
<source/>Brain
          <year>2013</year>
<volume>136</volume>
<fpage>3151</fpage>
<lpage>3162</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awt212</pub-id>
<pub-id pub-id-type="pmid">24014519</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bien</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Urbach</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schramm</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy</article-title>
<source/>Neurology
          <year>2007</year>
<volume>69</volume>
<fpage>1236</fpage>
<lpage>1244</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000276946.08412.ef</pub-id>
<pub-id pub-id-type="pmid">17875912</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanli-Yavuz</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Erdag</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tuzun</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2016</year>
<volume>87</volume>
<fpage>684</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2016-313146</pub-id>
<pub-id pub-id-type="pmid">27151964</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brenner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>1028</fpage>
<lpage>1035</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12127</pub-id>
<pub-id pub-id-type="pmid">23464826</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Early identification of refractory epilepsy</article-title>
<source/>N Engl J Med
          <year>2000</year>
<volume>342</volume>
<fpage>314</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM200002033420503</pub-id>
<pub-id pub-id-type="pmid">10660394</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodie</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Outcomes in newly diagnosed epilepsy in adolescents and adults: insights across a generation in Scotland</article-title>
<source/>Seizure
          <year>2016</year>
<pub-id pub-id-type="pmid">27640741</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callaghan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schlesinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rodemer</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Remission and relapse in a drug-resistant epilepsy population followed prospectively</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<fpage>619</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02929.x</pub-id>
<pub-id pub-id-type="pmid">21269287</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luciano</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Shorvon</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>Results of treatment changes in patients with apparently drug-resistant chronic epilepsy</article-title>
<source/>Ann Neurol
          <year>2007</year>
<volume>62</volume>
<fpage>375</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21064</pub-id>
<pub-id pub-id-type="pmid">17253624</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heiman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pandis</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Seizure remission and relapse in adults with intractable epilepsy: a cohort study</article-title>
<source/>Epilepsia
          <year>2008</year>
<volume>49</volume>
<fpage>1440</fpage>
<lpage>1445</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01601.x</pub-id>
<pub-id pub-id-type="pmid">18410367</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coulter</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Huguenard</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons</article-title>
<source/>Ann Neurol
          <year>1989</year>
<volume>25</volume>
<fpage>582</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410250610</pub-id>
<pub-id pub-id-type="pmid">2545161</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jasper</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kershman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>FA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Electroencephalographic classification of the epilepsies</article-title>
<source/>Arch Neurol Psychiatry
          <year>1941</year>
<volume>45</volume>
<fpage>903</fpage>
<pub-id pub-id-type="doi">10.1001/archneurpsyc.1941.02280180015001</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glauser</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Cnaan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shinnar</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy</article-title>
<source/>N Engl J Med
          <year>2010</year>
<volume>362</volume>
<fpage>790</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa0902014</pub-id>
<pub-id pub-id-type="pmid">20200383</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Blumenfeld</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Long-term seizure remission in childhood absence epilepsy: might initial treatment matter?</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>551</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12551</pub-id>
<pub-id pub-id-type="pmid">24512528</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bomben</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Aiba</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Isolated P/Q calcium channel deletion in layer VI corticothalamic neurons generates absence epilepsy</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<fpage>405</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2555-15.2016</pub-id>
<pub-id pub-id-type="pmid">26758833</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szaflarski</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gotman</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The relationship between the localization of the generalized spike and wave discharge generators and the response to valproate</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>471</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12062</pub-id>
<pub-id pub-id-type="pmid">23294001</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>International League Against Epilepsy Consortium on Complex Epilepsies</collab>
</person-group>
<article-title>Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies</article-title>
<source/>Lancet Neurol
          <year>2014</year>
<volume>13</volume>
<fpage>893</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70171-1</pub-id>
<pub-id pub-id-type="pmid">25087078</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lal</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ruppert</surname>
<given-names>A-K</given-names>
</name>
<name>
<surname>Trucks</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies</article-title>
<source/>PLoS Genet
          <year>2015</year>
<volume>11</volume>
<fpage>e1005226</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1005226</pub-id>
<pub-id pub-id-type="pmid">25950944</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>W-C</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>S-I</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>H-S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A marker for Stevens–Johnson syndrome</article-title>
<source/>Nature
          <year>2004</year>
<volume>428</volume>
<fpage>386</fpage>
<pub-id pub-id-type="doi">10.1038/428486a</pub-id>
<pub-id pub-id-type="pmid">15042080</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J-J</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C-S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan</article-title>
<source/>N Engl J Med
          <year>2011</year>
<volume>364</volume>
<fpage>1126</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1009717</pub-id>
<pub-id pub-id-type="pmid">21428768</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horn</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Ater</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Carbamazepine-exacerbated epilepsy in children and adolescents</article-title>
<source/>Pediatr Neurol
          <year>1986</year>
<volume>2</volume>
<fpage>340</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="doi">10.1016/0887-8994(86)90074-3</pub-id>
<pub-id pub-id-type="pmid">3508708</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerrini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dravet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Genton</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lamotrigine and seizure aggravation in severe myoclonic epilepsy</article-title>
<source/>Epilepsia
          <year>1998</year>
<volume>39</volume>
<fpage>508</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1998.tb01413.x</pub-id>
<pub-id pub-id-type="pmid">9596203</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snoeijen-Schouwenaars</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Veendrick</surname>
<given-names>MJBM</given-names>
</name>
<name>
<surname>van Mierlo</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Carbamazepine and oxcarbazepine in adult patients with Dravet syndrome: friend or foe?</article-title>
<source/>Seizure
          <year>2015</year>
<volume>29</volume>
<fpage>114</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2015.03.010</pub-id>
<pub-id pub-id-type="pmid">26076853</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Del-Favero</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ceulemans</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy</article-title>
<source/>Am J Hum Genet
          <year>2001</year>
<volume>68</volume>
<fpage>1327</fpage>
<lpage>1332</lpage>
<pub-id pub-id-type="doi">10.1086/320609</pub-id>
<pub-id pub-id-type="pmid">11359211</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Petrou</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Sodium channels and the neurobiology of epilepsy</article-title>
<source/>Epilepsia
          <year>2012</year>
<volume>53</volume>
<fpage>1849</fpage>
<lpage>1859</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03631.x</pub-id>
<pub-id pub-id-type="pmid">22905747</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Millichap</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Spectrum of SCN8A-related epilepsy</article-title>
<source/>Pediatr Neurol Briefs
          <year>2015</year>
<volume>29</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.15844/pedneurbriefs-29-2-7</pub-id>
<pub-id pub-id-type="pmid">26933559</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy</article-title>
<source/>J Med Genet
          <year>2015</year>
<volume>52</volume>
<fpage>330</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102813</pub-id>
<pub-id pub-id-type="pmid">25725044</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boerma</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>van de Broek</surname>
<given-names>MPH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach</article-title>
<source/>Neurotherapeutics
          <year>2016</year>
<volume>13</volume>
<fpage>192</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-015-0372-8</pub-id>
<pub-id pub-id-type="pmid">26252990</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klepper</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet</article-title>
<source/>Epilepsia
          <year>2008</year>
<volume>49</volume>
<fpage>46</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01833.x</pub-id>
<pub-id pub-id-type="pmid">19049586</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leen</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Taher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verbeek</surname>
<given-names>MM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GLUT1 deficiency syndrome into adulthood: a follow-up study</article-title>
<source/>J Neurol
          <year>2014</year>
<volume>261</volume>
<fpage>589</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-014-7240-z</pub-id>
<pub-id pub-id-type="pmid">24413642</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wickenden</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels</article-title>
<source/>Mol Pharmacol
          <year>2000</year>
<volume>58</volume>
<fpage>591</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">10953053</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millichap</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsuchida</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>KCNQ2 encephalopathy</article-title>
<source/>Neurol Genet
          <year>2016</year>
<pub-id pub-id-type="pmid">27602407</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garin Shkolnik</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Feuerman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Didkovsky</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine</article-title>
<source/>JAMA Dermatol
          <year>2014</year>
<volume>150</volume>
<fpage>984</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="doi">10.1001/jamadermatol.2013.8895</pub-id>
<pub-id pub-id-type="pmid">25006968</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ortiz-Gonzalez</surname>
<given-names>XR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milligan</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gazina</surname>
<given-names>EV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>75</volume>
<fpage>581</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24128</pub-id>
<pub-id pub-id-type="pmid">24591078</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mikati</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quinidine in the treatment of KCNT1-positive epilepsies</article-title>
<source/>Ann Neurol
          <year>2015</year>
<volume>78</volume>
<fpage>995</fpage>
<lpage>999</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24520</pub-id>
<pub-id pub-id-type="pmid">26369628</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerrini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dobyns</surname>
<given-names>WB</given-names>
</name>
</person-group>
<article-title>Malformations of cortical development: clinical features and genetic causes</article-title>
<source/>Lancet Neurol
          <year>2014</year>
<volume>13</volume>
<fpage>710</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70040-7</pub-id>
<pub-id pub-id-type="pmid">24932993</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Care</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis</article-title>
<source/>N Engl J Med
          <year>2010</year>
<volume>363</volume>
<fpage>1801</fpage>
<lpage>1811</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1001671</pub-id>
<pub-id pub-id-type="pmid">21047224</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Citraro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Donato</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>69</volume>
<fpage>25</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.09.019</pub-id>
<pub-id pub-id-type="pmid">23092918</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Yapici</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study</article-title>
<source/>Lancet
          <year>2016</year>
<volume>6736</volume>
<fpage>1</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sosanya</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Brager</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rapamycin reveals an mTOR-independent repression of Kv1.1 expression during epileptogenesis</article-title>
<source/>Neurobiol Dis
          <year>2015</year>
<volume>73</volume>
<fpage>96</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.09.011</pub-id>
<pub-id pub-id-type="pmid">25270294</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gleichman</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>EG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies</article-title>
<source/>Lancet Neurol
          <year>2008</year>
<volume>7</volume>
<fpage>1091</fpage>
<lpage>1098</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(08)70224-2</pub-id>
<pub-id pub-id-type="pmid">18851928</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaswamy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>DB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammasome induction in Rasmussen’s encephalitis: cortical and associated white matter pathogenesis</article-title>
<source/>J Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>918</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-152</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zurolo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vezzani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Astrocyte immune responses in epilepsy</article-title>
<source/>Glia
          <year>2012</year>
<volume>60</volume>
<fpage>1258</fpage>
<lpage>1268</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22312</pub-id>
<pub-id pub-id-type="pmid">22331574</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balosso</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vezzani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The dual role of TNF-α and its receptors in seizures</article-title>
<source/>Exp Neurol
          <year>2013</year>
<volume>247</volume>
<fpage>267</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2013.05.010</pub-id>
<pub-id pub-id-type="pmid">23707217</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prabowo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anink</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential expression of major histocompatibility complex class I in developmental glioneuronal lesions</article-title>
<source/>J Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>12</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-12</pub-id>
<pub-id pub-id-type="pmid">23347564</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoda</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Vohora</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resveratrol suppressed seizures by attenuating IL-1β, IL1-Ra, IL-6, and TNF-α in the hippocampus and cortex of kindled mice</article-title>
<source/>Nutr Neurosci
          <year>2016</year>
<pub-id pub-id-type="pmid">27256583</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vezzani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bartfai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baram</surname>
<given-names>TZ</given-names>
</name>
</person-group>
<article-title>The role of inflammation in epilepsy</article-title>
<source/>Nat Rev Neurol
          <year>2011</year>
<volume>7</volume>
<fpage>31</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2010.178</pub-id>
<pub-id pub-id-type="pmid">21135885</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maroso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balosso</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice</article-title>
<source/>Neurotherapeutics
          <year>2011</year>
<volume>8</volume>
<fpage>304</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-011-0039-z</pub-id>
<pub-id pub-id-type="pmid">21431948</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janigro</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier</article-title>
<source/>Epilepsia
          <year>2012</year>
<volume>53</volume>
<fpage>26</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03472.x</pub-id>
<pub-id pub-id-type="pmid">22612806</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janigro</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iffland</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Marchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Granata</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>30</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12271</pub-id>
<pub-id pub-id-type="pmid">24001067</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zurolo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maroso</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of TLR, RAGE and HMGB1 signaling in malformations of cortical development</article-title>
<source/>Brain
          <year>2013</year>
<volume>134</volume>
<fpage>1015</fpage>
<lpage>1032</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awr032</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zurolo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Spliet</surname>
<given-names>WGM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias</article-title>
<source/>Epilepsia
          <year>2010</year>
<volume>51</volume>
<fpage>1763</fpage>
<lpage>1773</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02547.x</pub-id>
<pub-id pub-id-type="pmid">20345941</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>van den Munckhof</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>KPJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inflammatory mediators in human epilepsy: a systematic review and meta-analysis</article-title>
<source/>Neurosci Biobehav Rev
          <year>2016</year>
<volume>63</volume>
<fpage>177</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.02.007</pub-id>
<pub-id pub-id-type="pmid">26877106</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ritter</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Failla</surname>
<given-names>MD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IL-1-β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>1109</fpage>
<lpage>1119</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12628</pub-id>
<pub-id pub-id-type="pmid">24754437</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Pineda</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Auvin</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain</article-title>
<source/>J Neuroinflammation
          <year>2013</year>
<volume>10</volume>
<fpage>30</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-30</pub-id>
<pub-id pub-id-type="pmid">23442201</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jyonouchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Intractable epilepsy (IE) and responses to anakinra, a human recombinant IL-1 receptor agonist (IL-1ra): case reports</article-title>
<source/>J Clin Cell Immunol
          <year>2016</year>
<volume>7</volume>
<fpage>1</fpage>
<lpage>5</lpage>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dibbens</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Donatello</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in DEPDC5 cause familial focal epilepsy with variable foci</article-title>
<source/>Nat Genet
          <year>2013</year>
<volume>45</volume>
<fpage>546</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2599</pub-id>
<pub-id pub-id-type="pmid">23542697</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Heron</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>BM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in mammalian target of rapamycin regulator <italic>DEPDC5</italic> cause focal epilepsy with brain malformations</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>75</volume>
<fpage>782</fpage>
<lpage>787</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24126</pub-id>
<pub-id pub-id-type="pmid">24585383</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baulac</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marsan</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial focal epilepsy with focal cortical dysplasia due to <italic>DEPDC 5</italic> mutations</article-title>
<source/>Ann Neurol
          <year>2015</year>
<volume>77</volume>
<fpage>675</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24368</pub-id>
<pub-id pub-id-type="pmid">25623524</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weckhuysen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marsan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lambrecq</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia</article-title>
<source/>Epilepsia
          <year>2016</year>
<volume>57</volume>
<fpage>994</fpage>
<lpage>1003</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13391</pub-id>
<pub-id pub-id-type="pmid">27173016</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>CB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study</article-title>
<source/>Lancet
          <year>2009</year>
<volume>373</volume>
<fpage>1105</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(09)60214-2</pub-id>
<pub-id pub-id-type="pmid">19233461</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Annegers</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rocca</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>A population-based study of seizures brain injuries</article-title>
<source/>N Engl J Med
          <year>1998</year>
<volume>338</volume>
<fpage>20</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199801013380104</pub-id>
<pub-id pub-id-type="pmid">9414327</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marson</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Al-Kharusi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Alwaidh</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial</article-title>
<source/>Lancet (London, England)
          <year>2007</year>
<volume>369</volume>
<fpage>1000</fpage>
<lpage>1015</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60460-7</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glauser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ben-Menachem</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>551</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12074</pub-id>
<pub-id pub-id-type="pmid">23350722</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baulac</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Patten</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial</article-title>
<source/>Lancet Neurol
          <year>2012</year>
<volume>11</volume>
<fpage>579</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70105-9</pub-id>
<pub-id pub-id-type="pmid">22683226</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leitinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Trinka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gardella</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study</article-title>
<source/>Lancet Neurol
          <year>2016</year>
<volume>15</volume>
<fpage>1054</fpage>
<lpage>1062</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)30137-5</pub-id>
<pub-id pub-id-type="pmid">27571157</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pohlmann-Eden</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marson</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Noack-Rink</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study</article-title>
<source/>BMC Neurol
          <year>2016</year>
<volume>16</volume>
<fpage>149</fpage>
<pub-id pub-id-type="doi">10.1186/s12883-016-0663-7</pub-id>
<pub-id pub-id-type="pmid">27552848</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Adamolekun</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Lacosamide treatment of juvenile myoclonic epilepsy</article-title>
<source/>Seizure
          <year>2012</year>
<volume>21</volume>
<fpage>202</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2011.12.010</pub-id>
<pub-id pub-id-type="pmid">22281192</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yates</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wechsler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beller</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label extension study (P3.276)</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<issue>P3</issue>
<fpage>276</fpage>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Wechsler</surname>
<given-names>RT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial</article-title>
<source/>Neurology
          <year>2015</year>
<volume>85</volume>
<fpage>950</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000001930</pub-id>
<pub-id pub-id-type="pmid">26296511</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Gowers</surname>
<given-names>WR</given-names>
</name>
</person-group>
<source/>Epilepsy and other chronic convulsive disorders
          <year>1881</year>
<publisher-loc>London</publisher-loc>
<publisher-name>Churchill</publisher-name>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feigenbaum</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bergmann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Richmond</surname>
<given-names>SA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nonpsychotropic cannabinoid acts as a functional <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor blocker</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1989</year>
<volume>86</volume>
<fpage>9584</fpage>
<lpage>9587</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.86.23.9584</pub-id>
<pub-id pub-id-type="pmid">2556719</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Cilio</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>791</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12631</pub-id>
<pub-id pub-id-type="pmid">24854329</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porter</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy</article-title>
<source/>Epilepsy Behav
          <year>2013</year>
<volume>29</volume>
<fpage>574</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2013.08.037</pub-id>
<pub-id pub-id-type="pmid">24237632</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial</article-title>
<source/>Lancet Neurol
          <year>2016</year>
<volume>15</volume>
<fpage>270</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00379-8</pub-id>
<pub-id pub-id-type="pmid">26724101</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<mixed-citation publication-type="other">Young S (2013) Marijuana stops child’s severe seizures-CNN.com. In: CNN. <ext-link ext-link-type="uri" xlink:href="http://edition.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/">http://edition.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/</ext-link>. Accessed 18 Dec 2016</mixed-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soltesz</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Alger</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Kano</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy</article-title>
<source/>Nat Rev Neurosci
          <year>2015</year>
<volume>16</volume>
<fpage>264</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3937</pub-id>
<pub-id pub-id-type="pmid">25891509</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volkow</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Baler</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Compton</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>SRB</given-names>
</name>
</person-group>
<article-title>Adverse health effects of marijuana use</article-title>
<source/>N Engl J Med
          <year>2014</year>
<volume>370</volume>
<fpage>2219</fpage>
<lpage>2227</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra1402309</pub-id>
<pub-id pub-id-type="pmid">24897085</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ottman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Ettinger</surname>
<given-names>AB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comorbidities of epilepsy: results from the epilepsy comorbidities and health (EPIC) survey</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<fpage>308</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">21269285</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caplan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Siddarth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities</article-title>
<source/>Epilepsia
          <year>2008</year>
<volume>49</volume>
<fpage>1838</fpage>
<lpage>1846</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01680.x</pub-id>
<pub-id pub-id-type="pmid">18557780</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camfield</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Camfield</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>Long-term social outcomes for children with epilepsy</article-title>
<source/>Epilepsia
          <year>2007</year>
<volume>48</volume>
<fpage>3</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01390.x</pub-id>
<pub-id pub-id-type="pmid">18047590</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferro</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Camfield</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>SD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Trajectories of health-related quality of life in children with epilepsy: a cohort study</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>1889</fpage>
<lpage>1897</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12388</pub-id>
<pub-id pub-id-type="pmid">24116691</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sheth</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric comorbidity in children with new onset epilepsy</article-title>
<source/>Dev Med Child Neurol
          <year>2007</year>
<volume>49</volume>
<fpage>493</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2007.00493.x</pub-id>
<pub-id pub-id-type="pmid">17593119</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hesdorffer</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mynepalli</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy, suicidality, and psychiatric disorders: a bidirectional association</article-title>
<source/>Ann Neurol
          <year>2012</year>
<volume>72</volume>
<fpage>184</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1002/ana.23601</pub-id>
<pub-id pub-id-type="pmid">22887468</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazarati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sankar</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Common mechanisms underlying epileptogenesis and the comorbidities of epilepsy</article-title>
<source/>Cold Spring Harb Perspect Med
          <year>2016</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a022798</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lothe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Didelot</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hammers</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comorbidity between temporal lobe epilepsy and depression: a [18 F] MPPF PET study</article-title>
<source/>Brain
          <year>2008</year>
<volume>131</volume>
<fpage>2765</fpage>
<lpage>2782</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awn194</pub-id>
<pub-id pub-id-type="pmid">18765418</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Finegersh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>DM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy</article-title>
<source/>Neurology
          <year>2013</year>
<volume>80</volume>
<fpage>1465</fpage>
<lpage>1471</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e31828cf809</pub-id>
<pub-id pub-id-type="pmid">23516322</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larkin</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Beautrais</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2011</year>
<volume>14</volume>
<fpage>1127</fpage>
<lpage>1131</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145711000629</pub-id>
<pub-id pub-id-type="pmid">21557878</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Antidepressant drugs: indications and guidelines for use in epilepsy</article-title>
<source/>Epilepsia
          <year>2002</year>
<volume>43</volume>
<fpage>14</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1046/j.1528-1157.2002.043s2014.x</pub-id>
<pub-id pub-id-type="pmid">11903477</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harden</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Mood disorders in patients with epilepsy</article-title>
<source/>CNS Drugs
          <year>2002</year>
<volume>16</volume>
<fpage>291</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.2165/00023210-200216050-00002</pub-id>
<pub-id pub-id-type="pmid">11994019</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardamone</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Salzberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?</article-title>
<source/>Br J Pharmacol
          <year>2013</year>
<volume>168</volume>
<fpage>1531</fpage>
<lpage>1554</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12052</pub-id>
<pub-id pub-id-type="pmid">23146067</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanner</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence</article-title>
<source/>Epilepsy Behav
          <year>2016</year>
<volume>61</volume>
<fpage>282</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.03.022</pub-id>
<pub-id pub-id-type="pmid">27236241</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faingold</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Randall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serotonergic agents act on 5-HT3 receptors in the brain to block seizure-induced respiratory arrest in the DBA/1 mouse model of SUDEP</article-title>
<source/>Epilepsy Behav
          <year>2016</year>
<volume>64</volume>
<fpage>166</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.09.034</pub-id>
<pub-id pub-id-type="pmid">27743549</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boylan</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Labovitz</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy</article-title>
<source/>Neurology
          <year>2004</year>
<volume>62</volume>
<fpage>258</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000103282.62353.85</pub-id>
<pub-id pub-id-type="pmid">14745064</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2014</year>
<volume>85</volume>
<fpage>1029</fpage>
<lpage>1034</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2013-306318</pub-id>
<pub-id pub-id-type="pmid">24444855</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Pennell</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Management of epilepsy during pregnancy: an update</article-title>
<source/>Ther Adv Neurol Disord
          <year>2016</year>
<volume>9</volume>
<fpage>118</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1177/1756285615623934</pub-id>
<pub-id pub-id-type="pmid">27006699</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>LB</given-names>
</name>
</person-group>
<article-title>Comparative safety of antiepileptic drugs during pregnancy For the North American</article-title>
<source/>Neurology
          <year>2012</year>
<volume>78</volume>
<fpage>1692</fpage>
<lpage>1699</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3182574f39</pub-id>
<pub-id pub-id-type="pmid">22551726</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mawhinney</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Levetiracetam in pregnancy</article-title>
<source/>Neurology
          <year>2013</year>
<volume>80</volume>
<fpage>400</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e31827f0874</pub-id>
<pub-id pub-id-type="pmid">23303847</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meador</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Browning</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study</article-title>
<source/>Lancet Neurol
          <year>2013</year>
<volume>12</volume>
<fpage>244</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70323-X</pub-id>
<pub-id pub-id-type="pmid">23352199</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Prenatal valproate exposure and risk of autism spectrum disorders</article-title>
<source/>JAMA
          <year>2013</year>
<volume>309</volume>
<fpage>1696</fpage>
<lpage>1703</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2013.2270</pub-id>
<pub-id pub-id-type="pmid">23613074</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bromley</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Mawer</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2013</year>
<volume>84</volume>
<fpage>637</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2012-304270</pub-id>
<pub-id pub-id-type="pmid">23370617</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veiby</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Engelsen</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Gilhus</surname>
<given-names>NE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding</article-title>
<source/>JAMA Neurol
          <year>2013</year>
<volume>70</volume>
<fpage>1367</fpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2013.4290</pub-id>
<pub-id pub-id-type="pmid">24061295</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernández-Díaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mittendorf</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between topiramate and zonisamide use during pregnancy and low birth weight</article-title>
<source/>Obstet Gynecol
          <year>2014</year>
<volume>123</volume>
<fpage>21</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1097/AOG.0000000000000018</pub-id>
<pub-id pub-id-type="pmid">24463659</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Devenney</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>165</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12001</pub-id>
<pub-id pub-id-type="pmid">23167802</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vajda</surname>
<given-names>FJE</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Lander</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Teratogenesis in repeated pregnancies in antiepileptic drug-treated women</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03625.x</pub-id>
<pub-id pub-id-type="pmid">22882134</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nashef</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>SUDEP and epilepsy-related mortality in pregnancy</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>72</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12621</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jobst</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Cascino</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>R</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resective epilepsy surgery for drug-resistant focal epilepsy</article-title>
<source/>JAMA
          <year>2015</year>
<volume>313</volume>
<fpage>285</fpage>
<pub-id pub-id-type="doi">10.1001/jama.2014.17426</pub-id>
<pub-id pub-id-type="pmid">25602999</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Englot</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>PA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy surgery trends in the United States, 1990–2008</article-title>
<source/>Neurology
          <year>2012</year>
<volume>78</volume>
<fpage>1200</fpage>
<lpage>1206</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e318250d7ea</pub-id>
<pub-id pub-id-type="pmid">22442428</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmstaedter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>May</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>von Lehe</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Temporal lobe surgery in Germany from 1988 to 2008: diverse trends in etiological subgroups</article-title>
<source/>Eur J Neurol
          <year>2014</year>
<volume>21</volume>
<fpage>827</fpage>
<lpage>834</lpage>
<pub-id pub-id-type="doi">10.1111/ene.12322</pub-id>
<pub-id pub-id-type="pmid">24313982</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shorvon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tomson</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Sudden unexpected death in epilepsy</article-title>
<source/>Lancet
          <year>2011</year>
<volume>378</volume>
<fpage>2028</fpage>
<lpage>2038</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(11)60176-1</pub-id>
<pub-id pub-id-type="pmid">21737136</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tebo</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Evins</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Christos</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evolution of cranial epilepsy surgery complication rates: a 32-year systematic review and meta-analysis</article-title>
<source/>J Neurosurg
          <year>2014</year>
<volume>120</volume>
<fpage>1415</fpage>
<lpage>1427</lpage>
<pub-id pub-id-type="doi">10.3171/2014.1.JNS131694</pub-id>
<pub-id pub-id-type="pmid">24559222</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjellvi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Flink</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rydenhag</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Malmgren</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Complications of epilepsy surgery in Sweden 1996–2010: a prospective, population-based study</article-title>
<source/>J Neurosurg
          <year>2015</year>
<volume>122</volume>
<fpage>519</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.3171/2014.9.JNS132679</pub-id>
<pub-id pub-id-type="pmid">25361484</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rathore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sarma</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Radhakrishnan</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Feasibility of antiepileptic drug withdrawal following extratemporal resective epilepsy surgery</article-title>
<source/>Neurology
          <year>2012</year>
<volume>79</volume>
<fpage>770</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3182644f7d</pub-id>
<pub-id pub-id-type="pmid">22843256</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yardi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kayyali</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reducing versus stopping antiepileptic medications after temporal lobe surgery</article-title>
<source/>Ann Clin Transl Neurol
          <year>2014</year>
<volume>1</volume>
<fpage>115</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.35</pub-id>
<pub-id pub-id-type="pmid">25356390</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taft</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sager Magnusson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ekstedt</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Malmgren</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Health-related quality of life, mood, and patient satisfaction after epilepsy surgery in Sweden—a prospective controlled observational study</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>878</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12616</pub-id>
<pub-id pub-id-type="pmid">24701994</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picot</surname>
<given-names>M-C</given-names>
</name>
<name>
<surname>Jaussent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neveu</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: a 5-year follow-up study</article-title>
<source/>Epilepsia
          <year>2016</year>
<volume>57</volume>
<fpage>1669</fpage>
<lpage>1679</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13492</pub-id>
<pub-id pub-id-type="pmid">27595433</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edelvik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rydenhag</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term outcomes of epilepsy surgery in Sweden: a national prospective and longitudinal study</article-title>
<source/>Neurology
          <year>2013</year>
<volume>81</volume>
<fpage>1244</fpage>
<lpage>1251</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a6ca7b</pub-id>
<pub-id pub-id-type="pmid">23966252</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rydenhag</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Flink</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Malmgren</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Surgical outcomes in patients with epileptogenic tumours and cavernomas in Sweden: good seizure control but late referrals</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2013</year>
<volume>84</volume>
<fpage>49</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp-2012-302449</pub-id>
<pub-id pub-id-type="pmid">22952328</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Quigg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Starke</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Predictors of seizure improvement following stereotactic radiosurgery for cerebral arteriovenous malformations in a prospective cohort of 229 patients with AVM-associated epilepsy (P1.001)</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<issue>P1</issue>
<fpage>001</fpage>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Przybylowski</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Starke</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Seizure and anticonvulsant outcomes following stereotactic radiosurgery for intracranial arteriovenous malformations</article-title>
<source/>J Neurosurg
          <year>2015</year>
<volume>122</volume>
<fpage>1299</fpage>
<lpage>1305</lpage>
<pub-id pub-id-type="doi">10.3171/2014.11.JNS141388</pub-id>
<pub-id pub-id-type="pmid">25614948</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ditty</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Omar</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>PM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Seizure outcomes after stereotactic radiosurgery for the treatment of cerebral arteriovenous malformations</article-title>
<source/>J Neurosurg
          <year>2016</year>
<pub-id pub-id-type="pmid">27058198</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>E-S</given-names>
</name>
<name>
<surname>Sui</surname>
<given-names>C-B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T-X</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>G-L</given-names>
</name>
</person-group>
<article-title>Stereotactic radiosurgery for the treatment of mesial temporal lobe epilepsy</article-title>
<source/>Acta Neurol Scand
          <year>2016</year>
<volume>134</volume>
<fpage>442</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12562</pub-id>
<pub-id pub-id-type="pmid">26846702</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waseem</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Osborn</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Schoenberg</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Laser ablation therapy: an alternative treatment for medically resistant mesial temporal lobe epilepsy after age 50</article-title>
<source/>Epilepsy Behav
          <year>2015</year>
<volume>51</volume>
<fpage>152</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.07.022</pub-id>
<pub-id pub-id-type="pmid">26280814</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jagid</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MRI-guided stereotactic laser ablation of mesial temporal structures for the treatment of refractory temporal lobe epilepsy (S31.008)</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<issue>S31</issue>
<fpage>008</fpage>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Martinez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vadera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mullin</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Robot-assisted stereotactic laser ablation in medically intractable epilepsy</article-title>
<source/>Neurosurgery
          <year>2014</year>
<volume>10</volume>
<fpage>167</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1227/NEU.0000000000000286</pub-id>
<pub-id pub-id-type="pmid">24448180</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willie</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Laxpati</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Drane</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy</article-title>
<source/>Neurosurgery
          <year>2014</year>
<volume>74</volume>
<fpage>569</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.1227/NEU.0000000000000343</pub-id>
<pub-id pub-id-type="pmid">24618797</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wellmer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Voges</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Parpaley</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Lesion guided radiofrequency thermocoagulation (L-RFTC) for hypothalamic hamartomas, nodular heterotopias and cortical dysplasias: review and perspective</article-title>
<source/>Seizure
          <year>2016</year>
<volume>41</volume>
<fpage>206</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2016.05.013</pub-id>
<pub-id pub-id-type="pmid">27282837</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Tisi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Peacock</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study</article-title>
<source/>Lancet
          <year>2011</year>
<volume>378</volume>
<fpage>1388</fpage>
<lpage>1395</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(11)60890-8</pub-id>
<pub-id pub-id-type="pmid">22000136</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Martinez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bulacio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alexopoulos</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stereoelectroencephalography in the “difficult to localize” refractory focal epilepsy: early experience from a North American epilepsy center</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>323</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03672.x</pub-id>
<pub-id pub-id-type="pmid">23016576</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coan</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bergo</surname>
<given-names>FPG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>3T MRI quantification of hippocampal volume and signal in mesial temporal lobe epilepsy improves detection of hippocampal sclerosis</article-title>
<source/>AJNR Am J Neuroradiol
          <year>2014</year>
<volume>35</volume>
<fpage>77</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.3174/ajnr.A3640</pub-id>
<pub-id pub-id-type="pmid">23868151</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellerio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Labeyrie</surname>
<given-names>M-A</given-names>
</name>
<name>
<surname>Chassoux</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>3T MRI improves the detection of transmantle sign in type 2 focal cortical dysplasia</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>117</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12464</pub-id>
<pub-id pub-id-type="pmid">24237393</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Ciantis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barba</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tassi</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>7 T MRI in focal epilepsy with unrevealing conventional field strength imaging</article-title>
<source/>Epilepsia
          <year>2016</year>
<volume>57</volume>
<fpage>445</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13313</pub-id>
<pub-id pub-id-type="pmid">26778405</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathore</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Teotónio</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery</article-title>
<source/>Epilepsy Res
          <year>2014</year>
<volume>108</volume>
<fpage>1306</fpage>
<lpage>1314</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2014.06.012</pub-id>
<pub-id pub-id-type="pmid">25043753</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>P-F</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>J-S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H-J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term epilepsy surgery outcomes in patients with PET-positive, MRI-negative temporal lobe epilepsy</article-title>
<source/>Epilepsy Behav
          <year>2014</year>
<volume>41</volume>
<fpage>91</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2014.09.054</pub-id>
<pub-id pub-id-type="pmid">25461196</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagić</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Look back to leap forward: the emerging new role of magnetoencephalography (MEG) in nonlesional epilepsy</article-title>
<source/>Clin Neurophysiol
          <year>2016</year>
<volume>127</volume>
<fpage>60</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinph.2015.05.009</pub-id>
<pub-id pub-id-type="pmid">26055337</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>ZI</given-names>
</name>
<name>
<surname>Marashly</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Correlating magnetoencephalography to stereo-electroencephalography in patients undergoing epilepsy surgery</article-title>
<source/>Brain
          <year>2016</year>
<volume>139</volume>
<fpage>2935</fpage>
<lpage>2947</lpage>
<pub-id pub-id-type="doi">10.1093/brain/aww215</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lascano</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Perneger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vulliemoz</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Yield of MRI, high-density electric source imaging (HD-ESI), SPECT and PET in epilepsy surgery candidates</article-title>
<source/>Clin Neurophysiol
          <year>2016</year>
<volume>127</volume>
<fpage>150</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinph.2015.03.025</pub-id>
<pub-id pub-id-type="pmid">26021550</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oxley</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Opie</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>John</surname>
<given-names>SE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Minimally invasive endovascular stent-electrode array for high-fidelity, chronic recordings of cortical neural activity</article-title>
<source/>Nat Biotechnol
          <year>2016</year>
<volume>34</volume>
<fpage>320</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3428</pub-id>
<pub-id pub-id-type="pmid">26854476</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Révész</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rydenhag</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ben-Menachem</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Complications and safety of vagus nerve stimulation: 25 years of experience at a single center</article-title>
<source/>J Neurosurg Pediatr
          <year>2016</year>
<volume>18</volume>
<fpage>97</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.3171/2016.1.PEDS15534</pub-id>
<pub-id pub-id-type="pmid">27015521</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Englot</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Rolston</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>CW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy</article-title>
<source/>Neurosurgery
          <year>2016</year>
<volume>79</volume>
<fpage>345</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="doi">10.1227/NEU.0000000000001165</pub-id>
<pub-id pub-id-type="pmid">26645965</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryvlin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>DK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (open prospective randomized long-term effectiveness) trial</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>893</fpage>
<lpage>900</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12611</pub-id>
<pub-id pub-id-type="pmid">24754318</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>JLR</given-names>
</name>
<name>
<surname>Martín-Sánchez</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs</article-title>
<source/>Eur Psychiatry
          <year>2012</year>
<volume>27</volume>
<fpage>147</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.eurpsy.2011.07.006</pub-id>
<pub-id pub-id-type="pmid">22137776</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heck</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>King-Stephens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>AD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS system pivotal trial</article-title>
<source/>Epilepsia
          <year>2014</year>
<volume>55</volume>
<fpage>432</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12534</pub-id>
<pub-id pub-id-type="pmid">24621228</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salanova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Witt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Worth</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<fpage>1017</fpage>
<lpage>1025</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000001334</pub-id>
<pub-id pub-id-type="pmid">25663221</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kowski</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Voges</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Heinze</surname>
<given-names>H-J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nucleus accumbens stimulation in partial epilepsy-A randomized controlled case series</article-title>
<source/>Epilepsia
          <year>2015</year>
<volume>56</volume>
<fpage>e78</fpage>
<lpage>e82</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12999</pub-id>
<pub-id pub-id-type="pmid">25940212</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kros</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eelkman Rooda</surname>
<given-names>OHJ</given-names>
</name>
<name>
<surname>De Zeeuw</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Hoebeek</surname>
<given-names>FE</given-names>
</name>
</person-group>
<article-title>Controlling cerebellar output to treat refractory epilepsy</article-title>
<source/>Trends Neurosci
          <year>2015</year>
<volume>38</volume>
<fpage>787</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2015.10.002</pub-id>
<pub-id pub-id-type="pmid">26602765</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krook-Magnuson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oijala</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy</article-title>
<source/>Nat Commun
          <year>2013</year>
<volume>4</volume>
<fpage>1376</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms2376</pub-id>
<pub-id pub-id-type="pmid">23340416</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>